JP2021526801A5 - - Google Patents
Info
- Publication number
- JP2021526801A5 JP2021526801A5 JP2020567832A JP2020567832A JP2021526801A5 JP 2021526801 A5 JP2021526801 A5 JP 2021526801A5 JP 2020567832 A JP2020567832 A JP 2020567832A JP 2020567832 A JP2020567832 A JP 2020567832A JP 2021526801 A5 JP2021526801 A5 JP 2021526801A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- variable region
- chain variable
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023150164A JP7700189B2 (ja) | 2018-06-07 | 2023-09-15 | 抗Ｔｉｅ２抗体およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682042P | 2018-06-07 | 2018-06-07 | |
| US62/682,042 | 2018-06-07 | ||
| KR10-2019-0066622 | 2019-06-05 | ||
| KR1020190066622A KR102898574B1 (ko) | 2018-06-07 | 2019-06-05 | Tie2에 결합하는 항체 및 이의 용도 |
| PCT/KR2019/006820 WO2019235856A1 (ko) | 2018-06-07 | 2019-06-05 | Tie2에 결합하는 항체 및 이의 용도 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023150164A Division JP7700189B2 (ja) | 2018-06-07 | 2023-09-15 | 抗Ｔｉｅ２抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021526801A JP2021526801A (ja) | 2021-10-11 |
| JP2021526801A5 true JP2021526801A5 (enExample) | 2022-05-31 |
| JP7390317B2 JP7390317B2 (ja) | 2023-12-01 |
Family
ID=69056780
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567832A Active JP7390317B2 (ja) | 2018-06-07 | 2019-06-05 | 抗Ｔｉｅ２抗体およびその使用 |
| JP2023150164A Active JP7700189B2 (ja) | 2018-06-07 | 2023-09-15 | 抗Ｔｉｅ２抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023150164A Active JP7700189B2 (ja) | 2018-06-07 | 2023-09-15 | 抗Ｔｉｅ２抗体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12024562B2 (enExample) |
| EP (2) | EP3805265A4 (enExample) |
| JP (2) | JP7390317B2 (enExample) |
| KR (1) | KR102898574B1 (enExample) |
| CN (1) | CN112399975B (enExample) |
| AU (2) | AU2019283520A1 (enExample) |
| CA (1) | CA3101506A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3136975C (en) | 2019-08-14 | 2024-06-25 | Pharmabcine Inc. | Anti-tie2 antibody and use thereof |
| PE20230414A1 (es) * | 2020-03-24 | 2023-03-07 | Genentech Inc | Agentes de fijacion a tie2 y metodos de uso |
| KR102899889B1 (ko) * | 2020-11-03 | 2025-12-18 | 한국생명공학연구원 | 신규 항-Tie2 항체 또는 이의 항원 결합 단편, 및 이의 용도 |
| US20240254240A1 (en) * | 2021-05-06 | 2024-08-01 | Institute For Basic Science | Tie2 agonistic antibodies and uses thereof |
| GEAP202416581A (en) * | 2022-01-13 | 2024-12-10 | Ingenia Therapeutics Inc | Vegf and tie2-binding fusion protein and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU689232B2 (en) * | 1994-02-10 | 1998-03-26 | Ludwig Institute For Cancer Research | An immunointeractive molecule which binds the (TIE)2/TEK receptor extracellular domain |
| AUPM379494A0 (en) * | 1994-02-10 | 1994-03-03 | Ludwig Institute For Cancer Research | Immunointeractive molecules - ii |
| JP2000041675A (ja) * | 1998-07-31 | 2000-02-15 | Nichirei Corp | ヒトｔｅｋに対する抗体 |
| US6376653B1 (en) * | 1998-09-28 | 2002-04-23 | Smithkline Beecham Plc | Tie2 antagonist antibodies |
| US6365154B1 (en) * | 1998-09-28 | 2002-04-02 | Smithkline Beecham Corporation | Tie2 agonist antibodies |
| US20090137416A1 (en) * | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US20040101920A1 (en) * | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| JP2011102273A (ja) | 2009-11-11 | 2011-05-26 | Shiseido Co Ltd | Ｔｉｅ２活性化剤、血管の成熟化、正常化又は安定化剤、リンパ管安定化剤並びにしわ防止・改善剤及びむくみ改善・予防剤 |
| US10316105B2 (en) * | 2011-08-19 | 2019-06-11 | Regeneron Pharmaceuticals, Inc. | Anti-TIE2 antibodies and uses thereof |
| ES2694411T3 (es) * | 2011-08-19 | 2018-12-20 | Regeneron Pharmaceuticals, Inc. | Anticuerpos anti-Tie2 y usos de los mismos |
| KR102196450B1 (ko) | 2013-09-17 | 2020-12-30 | 삼성전자주식회사 | Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제 |
| JP6346761B2 (ja) | 2014-03-07 | 2018-06-20 | 丸善製薬株式会社 | Ｔｉｅ２活性化剤、並びに医薬品組成物、及び経口組成物 |
| SG11201700271RA (en) | 2014-07-15 | 2017-04-27 | Astellas Pharma Inc | NOVEL ANTI-HUMAN Tie2 ANTIBODY |
| CN106994185B (zh) * | 2016-01-22 | 2021-04-06 | 何玉龙 | Tie2对视网膜及其他组织中静脉血管的保护作用及应用 |
| JP2018043949A (ja) | 2016-09-15 | 2018-03-22 | サンスター株式会社 | Ｔｉｅ２活性用組成物 |
-
2019
- 2019-06-05 CA CA3101506A patent/CA3101506A1/en active Pending
- 2019-06-05 EP EP19814472.7A patent/EP3805265A4/en active Pending
- 2019-06-05 JP JP2020567832A patent/JP7390317B2/ja active Active
- 2019-06-05 AU AU2019283520A patent/AU2019283520A1/en not_active Abandoned
- 2019-06-05 KR KR1020190066622A patent/KR102898574B1/ko active Active
- 2019-06-05 EP EP25173861.3A patent/EP4591878A3/en active Pending
- 2019-06-05 CN CN201980038199.8A patent/CN112399975B/zh active Active
-
2020
- 2020-12-03 US US17/111,413 patent/US12024562B2/en active Active
-
2023
- 2023-09-15 JP JP2023150164A patent/JP7700189B2/ja active Active
-
2024
- 2024-05-17 US US18/667,700 patent/US20250011438A1/en active Pending
-
2026
- 2026-03-18 AU AU2026202090A patent/AU2026202090A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240082418A1 (en) | Method for producing antibody-drug conjugate | |
| JP2023175830A5 (enExample) | ||
| CA2971278C (en) | Cysteine linked nanobody dimers | |
| TWI731856B (zh) | 抗c-Met抗體和抗c-Met抗體-細胞毒性藥物偶聯物及其醫藥用途 | |
| US9670275B2 (en) | Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors | |
| CA2975810C (en) | NANOBODY DIMERS LINKED VIA C-TERMINAL ENGINEERED CYSTEINS | |
| JPWO2019044947A1 (ja) | 抗体−薬物コンジュゲートの改良製造方法 | |
| JP2008520186A5 (enExample) | ||
| JP2020531472A (ja) | 免疫刺激因子トル様受容体７（ｔｌｒ７）アゴニストとしての、６−アミノ−７，９−ジヒドロ−８ｈ−プリン−８−オン誘導体 | |
| JP6943764B2 (ja) | Ｉｌ−１７ａ結合ポリペプチド | |
| US20250304717A1 (en) | Camptothecin derivative and ligand-drug conjugate | |
| JP2012524071A (ja) | 抗ＴＮＦ−α抗体およびその用途 | |
| JP2010509931A5 (enExample) | ||
| RS61493B1 (sr) | Konstrukti multispecifičnih antitela | |
| JP2017536091A (ja) | 多価メディトープ、メディトープ結合性抗体およびそれらの使用 | |
| WO2016165580A1 (zh) | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 | |
| JP2023543493A5 (enExample) | ||
| CN113195530A (zh) | 抗体融合蛋白、制备方法及其应用 | |
| CN108601832A (zh) | 抗c-Met抗体-细胞毒性药物偶联物的医药用途 | |
| JP7792044B2 (ja) | ヒト化抗ｉｌ－１ｒ３抗体及び使用方法 | |
| CA3164234A1 (en) | Multi-specific antibodies | |
| CN117024587A (zh) | 人IL-1β蛋白结合分子及其编码基因和应用 | |
| CN120981244A (zh) | Vhh抗体和其用途 | |
| CN115505041B (zh) | 抗EphA2抗体及其应用 | |
| TW202604959A (zh) | 抗EGFR×cMet雙特異性抗體的藥物偶聯物及其用途 |